SG11201906213UA - Modulating expression of polypeptides via new gene switch expression systems - Google Patents
Modulating expression of polypeptides via new gene switch expression systemsInfo
- Publication number
- SG11201906213UA SG11201906213UA SG11201906213UA SG11201906213UA SG11201906213UA SG 11201906213U A SG11201906213U A SG 11201906213UA SG 11201906213U A SG11201906213U A SG 11201906213UA SG 11201906213U A SG11201906213U A SG 11201906213UA SG 11201906213U A SG11201906213U A SG 11201906213UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- expression
- polypeptides
- blacksburg
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 102000015696 Interleukins Human genes 0.000 abstract 1
- 108010063738 Interleukins Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000002655 kraft paper Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- LZWZPGLVHLSWQX-XMMPIXPASA-N n'-(3,5-dimethylbenzoyl)-n'-[(3r)-2,2-dimethylhexan-3-yl]-2-ethyl-3-methoxybenzohydrazide Chemical compound C=1C(C)=CC(C)=CC=1C(=O)N([C@H](CCC)C(C)(C)C)NC(=O)C1=CC=CC(OC)=C1CC LZWZPGLVHLSWQX-XMMPIXPASA-N 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 229950004051 veledimex Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4635—Cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464404—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/23—On/off switch
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/90—Vectors containing a transposable element
Abstract
O C (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 July 2018 (19.07.2018) WIP0 1 PCT omit °nolo oil! nit ow (10) International Publication Number WO 2018/132494 Al (51) International Patent Classification: Cl 2N 15/10 (2006.01) G01N 33/68 (2006.01) Cl 2N 15/63 (2006.01) (21) International Application Number: PCT/US2018/013196 (22) International Filing Date: 10 January 2018 (10.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/444,775 10 January 2017 (10.01.2017) US 62/464,958 28 February 2017 (28.02.2017) US (71) Applicant: INTREXON CORPORATION [US/US]; 1750 Kraft Drive, Blacksburg, Virginia 24060 (US). (72) Inventors: SHAH, Rutul R.; 1750 Kraft Dr., Blacksburg, Virginia 24060 (US). REED, Thomas D.; 1750 Kraft Dr., Blacksburg, Virginia 24060 (US). BOLINGER, Cheryl G.; 1750 Kraft Dr., Blacksburg, Virginia 24060 (US). (74) Agent: MATA, David; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: MODULATING EXPRESSION OF POLYPEPTIDES VIA NEW GENE SWITCH EXPRESSION SYSTEMS CDS CD4 Ali Veledimex (nM) FIG. 13C (57) : Disclosed herein are polynucleotides encoding ligand-inducible gene switch polypeptides, and systems comprising gene switch polypeptides for modulating the expression of a heterologous gene and an interleukin in a host cell. The compositions, methods and systems described herein facilitate ligand dependent expression of polypeptides including but not limited to cytokines and antigen binding polypeptides. [Continued on next page] WO 2018/132494 Al MIDEDIMOMOIDEIREEMOMOIIIMMIEMOHMEHOIMIE Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762444775P | 2017-01-10 | 2017-01-10 | |
US201762464958P | 2017-02-28 | 2017-02-28 | |
PCT/US2018/013196 WO2018132494A1 (en) | 2017-01-10 | 2018-01-10 | Modulating expression of polypeptides via new gene switch expression systems |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201906213UA true SG11201906213UA (en) | 2019-08-27 |
Family
ID=61094600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201906213UA SG11201906213UA (en) | 2017-01-10 | 2018-01-10 | Modulating expression of polypeptides via new gene switch expression systems |
Country Status (11)
Country | Link |
---|---|
US (2) | US11692194B2 (en) |
EP (1) | EP3568474A1 (en) |
JP (2) | JP7288401B2 (en) |
KR (1) | KR20190102259A (en) |
CN (1) | CN110462040A (en) |
AU (1) | AU2018207281A1 (en) |
CA (1) | CA3049652A1 (en) |
IL (2) | IL310711A (en) |
SG (1) | SG11201906213UA (en) |
WO (1) | WO2018132494A1 (en) |
ZA (1) | ZA201904623B (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2938887C (en) * | 2014-02-14 | 2023-04-11 | Laurence J. N. Cooper | Chimeric antigen receptors and methods of making |
KR102523318B1 (en) | 2016-12-16 | 2023-04-18 | 비-모젠 바이오테크놀로지스, 인크. | Enhanced HAT family transposon-mediated gene delivery and associated compositions, systems, and methods |
US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
CN111511391A (en) * | 2017-10-18 | 2020-08-07 | 英特拉克森公司 | Polypeptide compositions comprising spacer regions |
EP3752203A1 (en) * | 2018-02-13 | 2020-12-23 | Novartis AG | Chimeric antigen receptor therapy in combination with il-15r and il15 |
WO2019246486A2 (en) | 2018-06-21 | 2019-12-26 | B-Mogen Biotechnologies, Inc. | ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS |
CA3105816A1 (en) * | 2018-07-10 | 2020-01-16 | Precigen, Inc. | Ror-1 specific chimeric antigen receptors and uses thereof |
WO2020052645A1 (en) * | 2018-09-14 | 2020-03-19 | 上海原能细胞医学技术有限公司 | Cell containing immunomodulator on surface and use thereof |
CN110832071A (en) * | 2018-09-14 | 2020-02-21 | 上海原能细胞医学技术有限公司 | Cells comprising an immunomodulator on their surface and uses thereof |
JP2022513888A (en) * | 2018-12-14 | 2022-02-09 | プロヴィヴァ セラピューティクス (ホン コン) リミテッド | IL-15 composition and its usage |
WO2020206395A1 (en) * | 2019-04-05 | 2020-10-08 | Nektar Therapeutics | Method for enhancing cellular immunotherapy |
AU2020265652A1 (en) * | 2019-04-30 | 2021-12-02 | Atara Biotherapeutics, Inc. | Antigen specific CD19-targeted CAR-T cells |
EP3753566A1 (en) * | 2019-06-21 | 2020-12-23 | Medizinische Hochschule Hannover | All-in one viral vector for car and therapeutic effector molecule |
AU2020345943A1 (en) | 2019-09-10 | 2022-03-31 | Obsidian Therapeutics, Inc. | CA2-IL15 fusion proteins for tunable regulation |
EP3914699A4 (en) * | 2019-12-09 | 2023-03-29 | ImmunityBio, Inc. | Screening of cell clones expressing polygenic transgenes through non-antibiotic dependent positive selection |
CA3160614A1 (en) * | 2019-12-12 | 2021-06-17 | Marcela GUZMAN AYALA | Method and compositions for regulated armoring of cells |
WO2021164704A2 (en) * | 2020-02-19 | 2021-08-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Enhanced expression system and methods of use thereof |
WO2022109611A1 (en) | 2020-11-20 | 2022-05-27 | Simcere Innovation, Inc. | Armed dual car-t compositions and methods for cancer immunotherapy |
AU2021413365A1 (en) * | 2020-12-30 | 2023-07-20 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
JP2024517864A (en) * | 2021-05-04 | 2024-04-23 | ショアライン バイオサイエンシーズ, インク. | Therapeutic engineered cells |
WO2023076177A2 (en) * | 2021-10-25 | 2023-05-04 | Genvivo, Inc. | Compositions and methods for therapeutic delivery |
Family Cites Families (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5117057A (en) | 1985-10-21 | 1992-05-26 | Rohm And Haas Company | Insecticidal N' substituted-N-N'-disubstituted-hydrazines |
US4985461A (en) | 1985-10-21 | 1991-01-15 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-diacylhydrazines |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
FR2593630B1 (en) | 1986-01-27 | 1988-03-18 | Maurice Francois | DRAIN RESISTANCE ACTIVE MATRIX DISPLAY SCREEN AND METHODS OF MAKING SAME |
US5225443A (en) | 1986-05-01 | 1993-07-06 | Rohm And Haas Company | Insecticidal N'-substituted-N'-substituted N,N'-diacylhydrazines |
US6218525B1 (en) * | 1988-02-25 | 2001-04-17 | The General Hospital Corporation | Nucleic acid encoding CD28 |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US20040049014A1 (en) * | 1988-12-28 | 2004-03-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
CA2075192A1 (en) | 1990-03-22 | 1991-09-23 | Anthony E. Oro | Insect retinoid receptor compositions and methods |
CA2043775A1 (en) | 1990-06-14 | 1991-12-15 | Dat P. Le | Dibenzoylakylcyanohydrazines |
ATE159548T1 (en) | 1990-11-13 | 1997-11-15 | Immunex Corp | BIFUNCTIONAL SELECTABLE FUSION GENES |
IL100643A (en) | 1991-01-25 | 1996-10-31 | Nippon Kayaku Kk | Hydrazine derivatives and pesticidal compositions comprising such derivatives as effective component |
US6013836A (en) | 1992-02-28 | 2000-01-11 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-disubstitutedhydrazines |
US5530028A (en) | 1992-11-23 | 1996-06-25 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-diacylhydrazines |
US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
WO1994028143A1 (en) | 1993-05-21 | 1994-12-08 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
CA2213340C (en) | 1995-03-03 | 2011-07-26 | Novartis Ag | Control of gene expression in plants by receptor mediated transactivation in the presence of a chemical ligand |
ATE240119T1 (en) | 1995-03-08 | 2003-05-15 | Scripps Research Inst | ANTIGEN PRESENTATION SYSTEM AND ACTIVATION OF T CELLS |
US5785682A (en) * | 1995-03-22 | 1998-07-28 | Abbott Laboratories | Pre-filled syringe drug delivery system |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
US5885827A (en) | 1996-01-23 | 1999-03-23 | The Regents Of The Universtiy Of California | Eukaryotic high rate mutagenesis system |
IL126418A0 (en) | 1996-04-05 | 1999-05-09 | Salk Inst For Biological Studi | Hormone-mediated methods for modulating expression of exogenous genes and pharmaceutical compositions for modulating the same |
ATE347588T1 (en) | 1996-05-23 | 2006-12-15 | Scripps Research Inst | SYSTEMS FOR PRESENTATION OF CLASS II MHC ANTIGENS AND METHODS FOR ACTIVATION OF CD4?+ T LYMPHOCYTES |
EP0973928B1 (en) | 1997-03-11 | 2010-05-05 | Regents Of The University Of Minnesota | Dna-based transposon system for the introduction of nucleic acid into dna of a cell |
AU738494B2 (en) | 1997-07-10 | 2001-09-20 | Salk Institute For Biological Studies, The | Modified lepidopteran receptors and hybrid multifunctional proteins for use in regulation of transgene expression |
US6333318B1 (en) | 1998-05-14 | 2001-12-25 | The Salk Institute For Biological Studies | Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto |
US6790662B1 (en) | 1999-03-12 | 2004-09-14 | Ortho-Mcneil Pharmaceutical, Inc. | Method of isolating CD8+ cells, and related hybridoma cells antibodies and polypeptides |
AU5618200A (en) | 1999-06-18 | 2001-01-09 | Ariad Gene Therapeutics, Inc. | Chimeric oca-b transcription factors |
EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
AU1100201A (en) | 1999-10-28 | 2001-05-08 | Board Of Trustees Of The Leland Stanford Junior University | Methods of in vivo gene transfer using a sleeping beauty transposon system |
US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
JP2004500095A (en) | 2000-02-24 | 2004-01-08 | エクサイト セラピーズ, インコーポレイテッド | Simultaneous stimulation and enrichment of cells |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US20040033600A1 (en) | 2001-03-21 | 2004-02-19 | Palli Subba Reddy | Ecdysone receptor-based inducible gene expression system |
AU2001249315A1 (en) | 2000-03-22 | 2001-10-03 | Rheogene, Inc. | Ecdysone receptor-based inducible gene expression system |
AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
US8105825B2 (en) | 2000-10-03 | 2012-01-31 | Intrexon Corporation | Multiple inducible gene regulation system |
WO2002066615A2 (en) | 2001-02-20 | 2002-08-29 | Rheogene, Inc. | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
MXPA03007493A (en) | 2001-02-20 | 2004-10-15 | Rheogene Holdings Inc | Novel ecdysone receptor/invertebrate retinoid x receptor-based inducible gene expression system. |
EP1373470B1 (en) | 2001-02-20 | 2013-04-24 | Intrexon Corporation | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
US20040071671A1 (en) | 2001-02-20 | 2004-04-15 | Leturcq Didier J. | Cell therapy method for the treatment of tumors |
DK1572862T3 (en) | 2001-02-20 | 2012-11-26 | Intrexon Corp | Chimeric, retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system |
MXPA04002810A (en) | 2001-09-26 | 2005-06-06 | Rheogene Holdings Inc | Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof. |
CA2459807C (en) | 2001-09-26 | 2013-09-03 | Jianzhong Zhang | Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof |
US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
WO2003089618A2 (en) | 2002-04-22 | 2003-10-30 | Regents Of The University Of Minnesota | Transposon system and methods of use |
US7375093B2 (en) | 2002-07-05 | 2008-05-20 | Intrexon Corporation | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
US7569664B2 (en) | 2002-10-09 | 2009-08-04 | Immunocore Limited | Single chain recombinant T cell receptors |
US7304161B2 (en) | 2003-02-10 | 2007-12-04 | Intrexon Corporation | Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex |
US7304162B2 (en) | 2003-02-21 | 2007-12-04 | Intrexon Corporation | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
US7456315B2 (en) | 2003-02-28 | 2008-11-25 | Intrexon Corporation | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
US8802643B1 (en) | 2003-05-30 | 2014-08-12 | University Of South Florida | Method for the treatment of malignancies |
US7985739B2 (en) | 2003-06-04 | 2011-07-26 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced sleeping beauty transposon system and methods for using the same |
NZ570709A (en) | 2003-06-13 | 2010-04-30 | Univ Pennsylvania | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
US7935510B2 (en) | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
EP3363907A1 (en) | 2004-05-27 | 2018-08-22 | The Trustees of the University of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
JP5563194B2 (en) | 2004-06-29 | 2014-07-30 | イムノコア リミテッド | Cells expressing modified T cell receptors |
US7847064B2 (en) * | 2004-07-09 | 2010-12-07 | Donald Danforth Plant Science Center | Methods and compositions for regulating gene expression in plant cells |
ES2382775T3 (en) | 2004-10-08 | 2012-06-13 | Government Of The United States Of America,As Represented By The Secretary, Department Of Health And Human Services | Adoptive immunotherapy with enhanced T lymphocyte survival. |
MX2007014474A (en) | 2005-05-17 | 2008-02-07 | Univ Connecticut | Compositions and methods for immunomodulation in an organism. |
EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
BRPI0708446A2 (en) | 2006-03-01 | 2011-06-07 | Janssen Pharmaceutica Nv | cancer treatment by combining lymph node depletion agent with ctls and cytokines |
AU2007257683A1 (en) * | 2006-06-12 | 2007-12-21 | Symphogen A/S | Pan-cell surface receptor- specific therapeutics |
ES2603418T3 (en) | 2006-10-04 | 2017-02-27 | Janssen Pharmaceutica Nv | Preparation of inactivated artificial antigen presenting cells and their use in cell therapies |
US8603950B2 (en) | 2007-02-20 | 2013-12-10 | Anaptysbio, Inc. | Methods of generating libraries and uses thereof |
ES2529166T3 (en) | 2007-03-30 | 2015-02-17 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands in T lymphocytes transferred adoptively |
NZ599338A (en) | 2007-06-27 | 2013-11-29 | Marinepolymer Tech Inc | Complexes of il-15 and il-15ralpha and uses thereof |
US9228180B2 (en) | 2007-07-04 | 2016-01-05 | Max-Delbruck-Centrum Fur Molekulare Medizin | Polypeptide variants of sleeping beauty transposase |
EP2205249B1 (en) | 2007-09-28 | 2018-11-07 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
RU2484132C2 (en) | 2007-10-08 | 2013-06-10 | Интрексон Корпорейшн | Modified dendrite cells and their use in treatment of malignant tumours |
CA2718494C (en) | 2008-03-14 | 2016-05-17 | Intrexon Corporation | Steroidal ligands and their use in gene switch modulation |
KR101361416B1 (en) | 2008-10-08 | 2014-02-21 | 인트렉손 코포레이션 | Engineered cells expressing multiple immunomodulators and uses thereof |
WO2010126766A1 (en) * | 2009-04-30 | 2010-11-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible interleukin-12 |
JP5508625B2 (en) | 2009-12-14 | 2014-06-04 | トヨタ自動車株式会社 | Vehicle control apparatus and vehicle control method |
CN103038343A (en) | 2010-03-23 | 2013-04-10 | 英特瑞克斯顿股份有限公司 | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof. |
US9331524B1 (en) | 2010-07-03 | 2016-05-03 | Best Energy Reduction Technologies, Llc | Method, system and apparatus for monitoring and measuring power usage |
WO2012122025A2 (en) | 2011-03-04 | 2012-09-13 | Intrexon Corporation | Vectors conditionally expressing protein |
EA201791693A1 (en) * | 2011-03-25 | 2018-05-31 | Гленмарк Фармасьютикалс С.А. | HETERODIMERNY IMMUNOHLOBULINS |
US9266960B2 (en) * | 2011-04-08 | 2016-02-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer |
US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
CN105122032B (en) | 2013-03-12 | 2018-10-12 | 生物辐射实验室股份有限公司 | Colloidal Comassie stain |
CN105408473B9 (en) | 2013-05-14 | 2021-09-17 | 得克萨斯州大学***董事会 | Human applications of engineered Chimeric Antigen Receptor (CAR) T cells |
EP3004168A4 (en) | 2013-05-24 | 2017-03-01 | Board of Regents, The University of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
WO2014193898A1 (en) * | 2013-05-31 | 2014-12-04 | Merck Sharp & Dohme Corp. | Combination therapies for cancer |
US20170002378A1 (en) * | 2013-11-29 | 2017-01-05 | Ucb Biopharma Sprl | Synthetic Promoters |
US20160311879A1 (en) | 2013-12-18 | 2016-10-27 | Intrexon Corporation | Single chain il-12 nucleic acids, polypeptides, and uses thereof |
RU2021114500A (en) * | 2014-02-10 | 2021-06-07 | Мерк Патент Гмбх | TARGETED TGFβ INHIBITION |
US9814215B2 (en) | 2014-03-11 | 2017-11-14 | Little Big Cat, Inc. | Pet toy with telescoping wand with metallic wire |
EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
US20170037431A1 (en) * | 2014-05-01 | 2017-02-09 | University Of Washington | In vivo Gene Engineering with Adenoviral Vectors |
US10428305B2 (en) | 2014-05-15 | 2019-10-01 | National University Of Singapore | Modified natural killer cells that express IL15 and uses thereof |
WO2015187528A1 (en) * | 2014-06-02 | 2015-12-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting cd-19 |
US11030531B2 (en) | 2014-06-06 | 2021-06-08 | Trustees Of Boston University | DNA recombinase circuits for logical control of gene expression |
ES2811974T3 (en) | 2014-07-29 | 2021-03-15 | Novartis Ag | Dose escalation regimens of il-15 and il-15ralpha heterodimer for treating conditions |
TWI751102B (en) | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | Antibodies and chimeric antigen receptors specific for cd19 |
EP3197911A4 (en) | 2014-09-22 | 2018-06-20 | Intrexon Corporation | Improved therapeutic control of heterodimeric and single chain forms of interleukin-12 |
JP2017535284A (en) | 2014-11-05 | 2017-11-30 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | Genetically modified immune effector cells and genetically engineered cells for expansion of immune effector cells |
KR102656470B1 (en) | 2014-12-10 | 2024-04-09 | 리전츠 오브 더 유니버스티 오브 미네소타 | Genetically modified cells, tissues, and organs for treating disease |
WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
RU2020127887A (en) | 2015-03-11 | 2020-10-02 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | POLYPEPTIDES TRANSPOSE AND THEIR APPLICATION |
AU2016275030B2 (en) * | 2015-06-10 | 2021-12-09 | Nantkwest, Inc. | Modified NK-92 cells for treating cancer |
CA2999294A1 (en) | 2015-09-25 | 2017-03-30 | Altor Bioscience Corporation | Interleukin-15 superagonist significantly enhances graft-versus-tumor activity |
SG11201802912PA (en) | 2015-10-10 | 2018-05-30 | Intrexon Corp | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
US11020429B2 (en) * | 2015-11-05 | 2021-06-01 | Juno Therapeutics, Inc. | Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy |
WO2017083750A1 (en) | 2015-11-11 | 2017-05-18 | Intrexon Corporation | Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies |
CN106967685B (en) * | 2016-01-13 | 2020-06-02 | 北京马力喏生物科技有限公司 | Transgenic lymphocytes co-expressing anti-EGFRvIII chimeric antigen receptor and immune checkpoint inhibitory molecules and uses thereof |
US20190117690A1 (en) | 2016-04-06 | 2019-04-25 | The University State Of America As Represented By The Secretary Of The Department Of Health And Hum | Use of heterodimeric il-15 in adoptive cell transfer |
PL3377637T3 (en) * | 2016-04-08 | 2020-09-07 | Krystal Biotech, Inc. | Compositions for use in methods for the treatment of wounds, disorders, and diseases of the skin |
CN110997920A (en) | 2017-06-07 | 2020-04-10 | 英特拉克森公司 | Expression of novel cell tags |
-
2018
- 2018-01-10 EP EP18702387.4A patent/EP3568474A1/en active Pending
- 2018-01-10 CA CA3049652A patent/CA3049652A1/en active Pending
- 2018-01-10 KR KR1020197023025A patent/KR20190102259A/en not_active Application Discontinuation
- 2018-01-10 CN CN201880017197.6A patent/CN110462040A/en active Pending
- 2018-01-10 US US15/867,500 patent/US11692194B2/en active Active
- 2018-01-10 IL IL310711A patent/IL310711A/en unknown
- 2018-01-10 WO PCT/US2018/013196 patent/WO2018132494A1/en unknown
- 2018-01-10 AU AU2018207281A patent/AU2018207281A1/en active Pending
- 2018-01-10 IL IL267865A patent/IL267865B1/en unknown
- 2018-01-10 SG SG11201906213UA patent/SG11201906213UA/en unknown
- 2018-01-10 JP JP2019537292A patent/JP7288401B2/en active Active
-
2019
- 2019-07-15 ZA ZA2019/04623A patent/ZA201904623B/en unknown
-
2020
- 2020-05-22 US US16/881,871 patent/US11946054B2/en active Active
-
2023
- 2023-02-10 JP JP2023018898A patent/JP2023065438A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL267865B1 (en) | 2024-03-01 |
WO2018132494A1 (en) | 2018-07-19 |
CA3049652A1 (en) | 2018-07-19 |
ZA201904623B (en) | 2023-12-20 |
EP3568474A1 (en) | 2019-11-20 |
US20180291384A1 (en) | 2018-10-11 |
US20200283778A1 (en) | 2020-09-10 |
IL267865A (en) | 2019-09-26 |
JP7288401B2 (en) | 2023-06-07 |
AU2018207281A1 (en) | 2019-07-18 |
US11946054B2 (en) | 2024-04-02 |
CN110462040A (en) | 2019-11-15 |
US11692194B2 (en) | 2023-07-04 |
IL310711A (en) | 2024-04-01 |
KR20190102259A (en) | 2019-09-03 |
JP2023065438A (en) | 2023-05-12 |
JP2020513777A (en) | 2020-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201906213UA (en) | Modulating expression of polypeptides via new gene switch expression systems | |
SG11201907713WA (en) | Nucleic acid based data storage | |
SG11201901563UA (en) | De novo synthesized nucleic acid libraries | |
SG11201906264YA (en) | Improved serum albumin binders | |
SG11201908796XA (en) | Improved antigen binding receptors | |
SG11201909724RA (en) | Systems and processes for conversion of crude oil | |
SG11201808196UA (en) | Neoantigens and methods of their use | |
SG11201811025VA (en) | Systems and methods for automated annotation and screening of biological sequences | |
SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
SG11201906341XA (en) | Improved serum albumin binders | |
SG11201903935PA (en) | Production of carbon blacks and resins from hydrotreated catalytic slurry oil | |
SG11201908319WA (en) | Methods and systems for printing biological material | |
SG11201908784TA (en) | Improved antigen binding receptor formats | |
SG11201901221YA (en) | Methods for detecting aav | |
SG11201407508RA (en) | Encoding and decoding based on blending of sequences of samples along time | |
SG11201909011PA (en) | Niraparib compositions | |
SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
SG11201906468TA (en) | Chimeric antigen receptors against axl or ror2 and methods of use thereof | |
SG11201807881VA (en) | Compositions and methods for making antibodies based on use of an expression-enhancing locus | |
SG11201906142QA (en) | Conversion of crude oil to aromatic and olefinic petrochemicals | |
SG11201407818PA (en) | High-capacity storage of digital information in dna | |
SG11201407343XA (en) | Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof | |
SG11201906152RA (en) | Conversion of crude oil to aromatic and olefinic petrochemicals | |
SG11201907671XA (en) | Systems and methods for cracking hydrocarbon streams such as crude oils utilizing catalysts which include zeolite mixtures | |
SG11201908456VA (en) | Linker units and molecular constructs comprising same |